Epidemiology and antifungal susceptibility patterns of candidemia from a tertiary centre in Western Australia
Autor: | Dianne Gardam, Peter Boan |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Antifungal medicine.medical_specialty Antifungal Agents Candida parapsilosis Echinocandin medicine.drug_class 030106 microbiology Microbial Sensitivity Tests Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Drug Resistance Fungal Epidemiology Prevalence Humans Medicine Pharmacology (medical) Candida albicans Retrospective Studies Pharmacology biology Candida glabrata business.industry Mortality rate Australia Candidemia biochemical phenomena metabolism and nutrition equipment and supplies bacterial infections and mycoses biology.organism_classification Infectious Diseases Oncology chemistry 030220 oncology & carcinogenesis Caspofungin business Fluconazole medicine.drug |
Zdroj: | Journal of Chemotherapy. 31:137-140 |
ISSN: | 1973-9478 1120-009X 2005-2014 |
DOI: | 10.1080/1120009x.2019.1595895 |
Popis: | Candidemia is a common invasive fungal infection with a high mortality rate. We performed a retrospective audit of candidemia at a tertiary centre in Western Australia, 2005-2014. There were 167 episodes of candidemia due to 173 isolates of Candida. Candida albicans (40.5%), Candida glabrata complex (30.6%), Candida parapsilosis complex (14.4%) were the most common species causing candidemia across the study. Of the tested isolates, 17.7% (11/62) were non-susceptible to fluconazole and 13.6% (9/66) non-susceptible to caspofungin. 22.8% (8/35) C. glabrata complex were fluconazole resistant and 17.1% (6/35) were non-susceptible to caspofungin. Candida glabrata complex was more common in the latter time period, but there were no susceptibility changes over time. In our setting, the prevalence of C. glabrata complex and antifungal non-susceptibility is high, and the prevalence of C. glabrata complex is increasing. |
Databáze: | OpenAIRE |
Externí odkaz: |